Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-08-15
2000-11-21
Owens, Amelia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549408, A61K 31355
Patent
active
061504025
ABSTRACT:
Compounds, methods and compositions are provided for inducing natriuresis in a mammal. Methods for isolating and synthesizing the natriuretic compounds are also provided. Therapeutic methods using the natriuretic compounds are also provided. The natriuretic compounds are capable of inducing sodium excretion in a mammal without inducing corresponding prolongated potassium excretion.
REFERENCES:
patent: 3726904 (1973-04-01), Habicht et al.
patent: 3947473 (1976-03-01), Scott et al.
patent: 4237130 (1980-12-01), Cragoe et al.
patent: 4321270 (1982-03-01), Sundeen
Noal Cohen, Rocco Lopresti, Gabriel Saucy; A Novel Total Synthesis of (2R, 4'R, 8'R)-.alpha.-Tocopherol (Vitamin E). Construction of Chiral Chromans from an Optically Active, Nonaromatic Precursor; Journal of the American Chemical Society, 101:22, Oct. 24, 1979, pp 6710-6716.
U. Gloor, J. Wursch, U. Schwieter, O. Wiss; Resorption, Retention, Verteilung und Stoffwechsel des D,L-.alpha.-Tocopheramins, d,I-N-Methyl-.gamma.-Tocopheramins und des .gamma.-Tocopherols im Vergleich zum d,l-.alpha.-Tocopherol bei der Ratte; Helvetica Chimica Acta, vol. 49, 1966, No. 266-267, pp 2303-2312.
CA, p. 615, vol. 98, 1983; 98:71933r and JP, A, 57 145 871 (EISAI) Sep. 9, 1982; Hydroxychromanpropionic acid derivatives.
Chemical Abstracts, p. 416, vol. 100, 1984; 100: 136378v and J. Lipid Res., vol 25, No. 1, 1984, Engl., pp 40-48; Novel urinary metabolite of d-.delta.-tocopherol in rats.
Chemical Abstracts, p. 490, vol. 81, 1974; 151742s and Chem. Pharm. Bull., vol. 22., No. 3, 1974, JP pp 566-575; Ubuquinone and related compounds.
Chemical Abstracts, vol. 72, 1970, pp 383-384; 78856q and JP, A,6 927 026 (Taisho Pharmaceutical.) Nov. 11, 1969; Tocopheronolactone.
Chemical Abstracts, p. 2845, vol. 68, 1968; 29435k and JP, A, 1 303 467 (Yamanouchi) Jul. 28, 1967; Novel toluquinone derivatives.
Chemical Abstracts, p. 2512, vol. 69, 1968; 27057k and JP, A, 6 723 024 (Yamanouchi) Nov. 9, 1967; Novel 3,4-dimethoxytoluquinones.
CA: 106: 84395 (1985).
CA 120: 266482 (1993).
Derwent Abstract of JP 63208557 (A).
Free Radical Biology & Medicine, vol. 16 No. 4; Reduction of Myocardial Infarct Size in Rat by IRFI-048, A Selective Analogue of Vitamin E.
Pharmacology 1994; 48 pp. 157-166; Protective Effects of IRFI-016, a New Antioxidant Agent, in Myocardial Damage, following Coronary Artery Occlusion and Reperfusion in the Rat.
Research Communications in Chemical Pathology and Pharmacology, vol. 76, No. 3, pp. 287-303, Jun. 1992; IRFI-016, A New Radical Scavenger, Limits Ischemic Damage Following Coronary Artery Occlusion in Rats.
Benaksas Elaine J.
Kantoci Darko
Levine Barry H.
Murray David E.
Wechter William J.
Loma Linda University Medical Center
Owens Amelia
LandOfFree
Natriuretic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Natriuretic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Natriuretic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1257821